Attached files
| file | filename |
|---|---|
| 8-K - CURRENT REPORT - CASI Pharmaceuticals, Inc. | v327074_8k.htm |
November 1, 2012
Securities and Exchange Commission
Washington, D.C. 20549
Ladies and Gentlemen:
We have reviewed the disclosures concerning Reznick Group, P.C. made by EntreMed, Inc. in Item 4.01 of its Form 8-K, which we understand will be filed with the Securities and Exchange Commission on the date hereof, and are in agreement with the statements contained therein.
Very truly yours,
/s/ Reznick Group, P.C.